Viral Vector Manufacturing

Global Market Trajectory & Analytics

MCP15508

EXECUTIVE ENGAGEMENTS

POOL

13724
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

4666
Interactions with Platform & by Email

PARTICIPANTS

1120
Unique # Participated

VALIDATIONS

97
Responses Validated*

COMPANIES

80
Responses Validated*
* Login for a full stack data experience

DATE

JAN 2021

TABLES

144

PAGES

402

EDITION

7

PRICE

USD 5450

CODE

MCP15508


COMPETITIVE METRICS

COMPANY

RANK & SHARE

D S N T

% *

4D Molecular Therapeutics, Inc.

Login Required

Accelagen, Inc.

Login Required

Addgene, Inc.

Login Required

Advanced Bioscience Laboratories, Inc.

Login Required

Agilent Technologies, Inc.

Login Required

Akron Biotech

Login Required

Aldevron

Login Required

Algenex

Login Required

American Type Culture Collection (ATCC)

Login Required

Applied Viromics

Login Required

SUBMIT
* D = Dominant; S = Strong; N = Niche; T = Trivial (< 1%)
* Validated participants will receive complimentary Cluster data by email
Note: Best viewed in Landscape Mode
VIEW ENTIRE POOL OF 80 COMPETITORS

Sign-in with email to View Deeper Validated Engagement Details -

  

HIGHLIGHTS & REPORT INDEX

Global Viral Vector Manufacturing Market to Reach $1.2 Billion by 2026

Viral vectors are tools that find common usage in molecular biology related research, for the main purpose of delivering genetic materials to cells. The process of delivery is performed in vivo or inside the living organism and also in vitro or within cell culture. Viruses were able to evolve distinct molecular mechanisms which allow effective transmission of their genomes in the cells that they infect. The process of genetic material or genes delivery using a vector is called transduction. The cells that are infected are referred to as the transduced. Viral vectors were used by molecular biologists as early as in the 70s. SV40, a modified virus with DNA from bacteriophage ?, was used for infecting cells in monkey kidney. Viral vectors are currently being used for vaccines development and gene therapy in addition to their use in molecular biology. Though viral vectors are generally customized to suit specific applications, they have certain common properties in terms of safety, stability, toxicity, cell type specificity and identification. Usually, viral vectors are derived from viruses that are pathogenic. Modification is done to minimize risks while handling. Modification involves elimination of a viral genome part that is important for the replication of the virus. A modified virus requires helpers to produce new versions and therefore only effective for so long as to infect the cells. Another important property of viral vectors is that they are of low toxicity, having limited impact on cell physiology. Also, certain viruses are unstable genetically. They rearrange genomes rapidly which can be damaging to reproducibility and predictability of work done using viral vectors.

Amid the COVID-19 crisis, the global market for Viral Vector Manufacturing estimated at US$450.5 Million in the year 2020, is projected to reach a revised size of US$1.2 Billion by 2026, growing at a CAGR of 18.5% over the analysis period. Retroviral Vectors, one of the segments analyzed in the report, is projected to record a 18.5% CAGR and reach US$547.1 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Adenoviral Vectors segment is readjusted to a revised 18.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $327.6 Million in 2021, While China is Forecast to Reach $49 Million by 2026

The Viral Vector Manufacturing market in the U.S. is estimated at US$327.6 Million in the year 2021. China, the world`s second largest economy, is forecast to reach a projected market size of US$49 Million by the year 2026 trailing a CAGR of 21.9% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 15.8% and 16% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.1% CAGR.

The increasing prevalence of various genetic disorders and target diseases such as infectious diseases, increased funding availability for development of gene therapy, research efforts in the field of viral vector based cell and gene therapies, and increasing efficacy of viral vectors in delivering gene therapy are fueling growth in the global viral vectors manufacturing market. The growing investments into biopharmaceutical production, rising healthcare spending, technology advancements and healthcare needs of aging population are fueling growth in the viral vectors market. Rise in number of clinical studies, and potential applications in novel drug delivery approaches are also fueling growth in the market. Several viral vector-based drugs have already been approved including Gendicine™, which is the foremost gene therapy drug based on oncolytic adenovirus vector; StrimvelisR, a lentivirus vector for severe combined immunodeficiency (SCID); GlyberaRR, a recombinant AAV for addressing lipoprotein lipase deficiency.

Adeno-Associated Viral Vectors Segment to Reach $287.8 Million by 2026

AAVs or adeno-associated viruses are those that infect primate species and humans commonly. Even though they do not cause major diseases and only result in a minor immune response, the viruses are able to infect non-dividing as well as dividing cells and incorporate virus genome into host cell. AAV also stays in the form of episomal mostly, performing stable and long expression - features which make the viruses attractive candidates for viral vectors` creation, to be used in gene therapy. In the global Adeno-associated Viral Vectors segment, USA, Canada, Japan, China and Europe will drive the 19.7% CAGR estimated for this segment. These regional markets accounted for a combined market size of US$89.5 Million in the year 2020. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$8.2 Million by the year 2026.

SELECT PLAYERS

Batavia Biosciences B.V.; BioNTech IMFS GmbH; Cobra Biologics Ltd.; FinVector Oy; FUJIFILM Diosynth Biotechnologies; Genelux Corporation; Kaneka Eurogentec S.A.; Lonza Group AG; MaxCyte, Inc.; Merck KGaA; Novasep Inc.; Oxford BioMedica plc; Sirion-Biotech GmbH; Spark Therapeutics, Inc.; Thermo Fisher Scientific Inc.; Vector Biolabs; Vigene Biosciences, Inc.; Virovek, Inc.

SEGMENTS

» Type (Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors, Other Types) » Disease (Cancer, Genetic Disorders, Infectious Diseases, Other Diseases) » End-Use (Pharma & Biopharma Companies, Research Institutes)

GEOGRAPHIES

» World » USA » Canada » Japan » China » Europe » France » Germany » Italy » UK » Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Impact of COVID-19 Pandemic and Looming Global Recession
With Viral Vector-based Vaccines Used for COVID-19 in Development, Viral Vector Manufacturing Market Poised to Benefit
An Introduction to Viral Vector Manufacturing
Applications of Viral Vectors
Types of Viral Vectors
Global Viral Vector Manufacturing Market: Prospects & Outlook
Competition
COVID-19 Pandemic Puts Pressure on Already Constrained Viral Vector Manufacturing Capacity
A Glance at Select Investments in Expanding Viral Vector Manufacturing Capacity
Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Increasing Prevalence of Infectious Diseases, Genetic Disorders & Cancers Drives Market
EXHIBIT: Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
EXHIBIT: Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
EXHIBIT: Life Expectancy at Age 60 and 80 Years: (2010-2015), (2020-2025) & (2045-2050)
Gene Therapy Emerges as a Major Therapeutic Approach for Inheritable and Acquired Diseases, Spurring Market Prospects
Gene Therapy Set to Witness Rapid Growth Post COVID-19
Viral Vectors Lead the Gene Therapy Market
Adeno-Associated Virus Vectors: A Leading Platform for Gene Therapy
Lentiviral Vectors Witness Increased Interest for Gene Therapy
Funding Support for Gene Therapy Development Presents Market Opportunities
Complexity in Viral Vector Production for Gene therapies
Amidst Rising Cancer Incidence, Focus on Viral Vector-based Gene Therapies to Boost Market
EXHIBIT: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
EXHIBIT: Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018
EXHIBIT: Number of New Cancer Cases and Deaths (in Million) by Region for 2018
Engineered and Natural Oncolytic Viral Vectors: A Key Development in Viral Vector-based Cancer Therapy
Growing Threat Posed by Infectious Diseases Drives Focus onto Vector Viral-based Therapies & Vaccines
EXHIBIT: Infectious Diseases Remain Major Cause of Death in Under Developed Regions: Breakdown of Leading Causes of Death in Sub-Saharan Africa (in %)
EXHIBIT: Infectious Diseases Related Mortality High Among Children Below 5 Years: Breakdown of Leading Causes of Death in Children Below 5 Years (in %)
Rising Significance of Viral Vectors in New Vaccine Development
Adenovirus-based Vaccines: Evolution Over the Years
Viral Vector Emerges as a Next-Gen Platform for COVID-19 Vaccines Development
Rush to Develop and Rollout COVID-19 Vaccines Boosts Prospects for Viral Vector Manufacturing
EXHIBIT: COVID-19 Vaccines Under Development
EXHIBIT: Vaccines in Pipeline by Technology
EXHIBIT: Vaccine Technologies in Pre-Clinical Studies
Replicating and Non-Replicating Viral Vector-Based Vaccines
EXHIBIT: Non-Replicating Viral vector Vaccine in Clinical Development: As on December 2nd, 2020
EXHIBIT: Replicating Viral vector Vaccine Candidate in Clinical Development: As on December 2nd, 2020
Adenoviral Vectors: Frontrunners of New Vaccine for COVID-19
Vaccines for COVID-19 Confronts Logistic Obstacles to Overcome
Market to Benefit from the Emergence of New Technologies to Manufacture Viral Vectors
New Trends for Optimizing Workflow Using Viral Vectors
Production Workflow & Viral Vectors
Closed-System-Adherent Culture of Cells: Recent Advances
Limitations in Viral Vector Manufacturing Impact Market
Innovations & Collaborations: Essential to Resolve Challenges Facing Large-Scale GMP Viral Vector Manufacturing
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Viral Vector Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027
World Historic Review for Viral Vector Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
World 11-Year Perspective for Viral Vector Manufacturing by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2016, 2020 & 2027
World Current & Future Analysis for Retroviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027
World Historic Review for Retroviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
World 11-Year Perspective for Retroviral Vectors by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2020 & 2027
World Current & Future Analysis for Adenoviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027
World Historic Review for Adenoviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
World 11-Year Perspective for Adenoviral Vectors by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2020 & 2027
World Current & Future Analysis for Adeno-associated Viral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027
World Historic Review for Adeno-associated Viral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
World 11-Year Perspective for Adeno-associated Viral Vectors by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2020 & 2027
World Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027
World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
World 11-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2020 & 2027
World Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027
World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
World 11-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2020 & 2027
World Current & Future Analysis for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027
World Historic Review for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
World 11-Year Perspective for Genetic Disorders by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2020 & 2027
World Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027
World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
World 11-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2020 & 2027
World Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027
World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
World 11-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2020 & 2027
World Current & Future Analysis for Pharma & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027
World Historic Review for Pharma & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
World 11-Year Perspective for Pharma & Biopharma Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2020 & 2027
World Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027
World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
World 11-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
USA Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
USA 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2020 & 2027
USA Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
USA Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
USA 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2020 & 2027
USA Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
USA Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
USA 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2020 & 2027
CANADA
Canada Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
Canada Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
Canada 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2020 & 2027
Canada Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
Canada Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
Canada 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2020 & 2027
Canada Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
Canada Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
Canada 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
Japan Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
Japan 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2020 & 2027
Japan Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
Japan Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
Japan 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2020 & 2027
Japan Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
Japan Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
Japan 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2020 & 2027
CHINA
China Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
China Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
China 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2020 & 2027
China Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
China Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
China 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2020 & 2027
China Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
China Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
China 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2020 & 2027
EUROPE
Europe Current & Future Analysis for Viral Vector Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027
Europe Historic Review for Viral Vector Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
Europe 11-Year Perspective for Viral Vector Manufacturing by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2016, 2020 & 2027
Europe Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
Europe Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
Europe 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2020 & 2027
Europe Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
Europe Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
Europe 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2020 & 2027
Europe Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
Europe Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
Europe 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2020 & 2027
FRANCE
France Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
France Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
France 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2020 & 2027
France Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
France Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
France 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2020 & 2027
France Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
France Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
France 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
Germany Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
Germany 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2020 & 2027
Germany Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
Germany Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
Germany 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2020 & 2027
Germany Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
Germany Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
Germany 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2020 & 2027
ITALY
Italy Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
Italy Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
Italy 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2020 & 2027
Italy Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
Italy Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
Italy 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2020 & 2027
Italy Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
Italy Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
Italy 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
UK Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
UK 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2020 & 2027
UK Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
UK Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
UK 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2020 & 2027
UK Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
UK Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
UK 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
Rest of Europe Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
Rest of Europe 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2020 & 2027
Rest of Europe Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
Rest of Europe Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
Rest of Europe 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2020 & 2027
Rest of Europe Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
Rest of Europe Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
Rest of Europe 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
Asia-Pacific Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
Asia-Pacific 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2020 & 2027
Asia-Pacific Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
Asia-Pacific Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
Asia-Pacific 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2020 & 2027
Asia-Pacific Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
Asia-Pacific Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
Asia-Pacific 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
Rest of World Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
Rest of World 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2020 & 2027
Rest of World Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
Rest of World Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
Rest of World 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2020 & 2027
Rest of World Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027
Rest of World Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019
Rest of World 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2020 & 2027
Total Companies Profiled: 80

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com